权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations

CIVIC：乔治亚大学高危人群流感疫苗研究中心

基本信息

批准号：
10455390
负责人：
TED ROSS
金额：
$ 1227.56万
依托单位：
UNIVERSITY OF GEORGIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-10 至 2022-09-09
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10455390
关键词：
Adjuvant Animal Model Animals Area Bioinformatics Biological Assay Biometry Categories Contractor Contracts Couples Development Effectiveness Elderly Environment Evaluation Genetic Human Human Volunteers Immune Immune response Immunity Immunologics Immunology Individual Infection Modeling Mucous Membrane National Institute of Allergy and Infectious Disease Pathologic Phase I/II Clinical Trial Population Reagent Recording of previous events Research Research Design Research Personnel Resources Saint Jude Children&apos s Research Hospital Statistical Models Systems Biology United States National Institutes of Health Universities Vaccinated Vaccination Vaccine Design Vaccine Research Vaccines Vulnerable Populations Work anti-influenza base early phase clinical trial healthy volunteer high risk high risk population immunogenicity influenza virus vaccine innovation next generation novel novel vaccines obese person pre-clinical pregnant programs response seasonal influenza skills standard of care structural biology universal influenza vaccine universal vaccine vaccine candidate vaccine development vaccine response virology

项目摘要

The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”). This will be done through NIAID-supported Collaborative Influenza Vaccine Innovation Centers (CIVICs). Each CIVIC will support iterative vaccine design based on detailed immunologic assessment of influenza vaccine candidates through pre-clinical animal studies, early phase clinical trials and healthy volunteer human challenge studies to advance the most promising vaccine candidates into Phase I/II clinical trials. University of Georgia’s Center for Influenza Vaccine Research in High Risk Populations (CIVR-HRP) builds upon many years of collaborative work by the primary investigators, and proposes a comprehensive research program centering on identifying broadly protective influenza vaccines for all populations with a focus on our most vulnerable populations. The program couples the skills of established and junior investigators, and combines our historical program strengths in vaccine development, virology, immunology, animal models, validated assay and reagent development, systems biology, bioinformatics and structural biology, and their extensive and world-class facilities and resources including St Jude Children’s Research Hospital (SJCRH) GMP facility with novel and innovative study designs such as comprehensive assessment of immune and omics responses to vaccination, novel platforms and adjuvants, and exploration of immune correlates of protective immunity in high-risk populations.

该合同计划的目的是支持改善季节性流感疫苗的免疫原性和耐久性，并开发创新的流感疫苗方法，提供强大、持久、广泛保护的粘膜和全身抗流感免疫力（“通用流感疫苗”）。这将通过NIAID支持的合作流感疫苗创新中心（CIVIC）完成。每个CIVIC将通过临床前动物研究、早期临床试验和健康志愿者人体挑战研究，支持基于流感候选疫苗详细免疫学评估的迭代疫苗设计，以将最有希望的候选疫苗推进I/II期临床试验。格鲁吉亚大学的高危人群流感疫苗研究中心（CIVR-HRP）建立在主要研究者多年合作的基础上，提出了一项全面的研究计划，重点是为所有人群确定广泛保护性的流感疫苗，重点是我们最脆弱的人群。该计划结合了既定和初级研究人员的技能，并结合了我们在疫苗开发，病毒学，免疫学，动物模型，验证检测和试剂开发，系统生物学，生物信息学和结构生物学方面的历史计划优势，以及他们广泛的世界一流的设施和资源，包括圣裘德儿童研究医院（SJCRH）GMP设施具有新颖和创新的研究设计，例如对疫苗接种的免疫和组学反应的综合评估，新型平台和佐剂，以及对高危人群保护性免疫的免疫相关性的探索。